Boyds has been presented with one of the UK’s most prestigious business awards – The Queen’s Award for Enterprise, International Trade for Outstanding Short-Term Growth in overseas sales for the last three years, and specifically for its work in cell and gene therapy.
Boyds was awarded the accolade by Her Majesty’s Lord Lieutenant of Cheshire, Mr David Briggs, MBE, KStJ, in an official visit to Electra House, Crewe Business Park – the company’s Cheshire office – on Monday 10th September. Founder and CEO, Professor Alan Boyd, received a Grant of Appointment and commemorative crystal bowl in recognition of the company’s growth and commercial success in international trade.
Around 40 guests attended the evening event, including staff, clients and contacts of Boyds as well as the Mayor of Crewe and the High Sheriff of Cheshire.
Boyds was established 13 years ago, and now employs 20 members of staff and consultants working out of its offices in Cheshire and Cambridgeshire.
Working with small pharmaceutical and biotechnology companies as well as medical departments at universities, the team at Boyds helps to translate research ideas into medicines to treat human diseases. The business provides a range of expertise and skills central to the development of these medicinal products.
Boyds’ expert assistance also helps to expedite the development of medicines, adding value to these products, and helping businesses reach key milestones in their drug development projects. Working in a highly regulated global industry, Boyds has grown its overseas sales by two thirds in the last three years with profits more than doubling.
Boyds’ success in winning the Award also means it can fly the Queen’s Award flag at its head office in Crewe and feature the emblem on its marketing materials.
Professor Alan Boyd commented, “We were truly delighted to receive the prestigious Queen’s Award for Enterprise from Her Majesty’s Lord Lieutenant of Cheshire in a ceremony at our Crewe office, where we were joined by those who have helped make the company the success it is today.
“It is a great privilege to have a globally-recognised royal stamp of approval, particularly as around 60% of our revenue now comes from businesses based outside the UK.
“We have a clear vision moving forward to continue to use our knowledge and expertise to help our global clients to develop products for the benefit of patients.”
